Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association between polymorphisms in the thymidylate synthase gene and risk of breast cancer in a Mexican population.
|
25366766 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that 3 copies of the TYMS 5'UTR repeat may give a treatment specific reduced survival in breast cancer patients, and that TP53 may have a direct, allele specific, role in 5-FU mediated response.
|
18498133 |
2008 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The expression of drug-metabolizing genes, including excision repair cross‑complementing 1 (ERCC1), orotate phosphoribosyltransferase (OPRT), thymidylate synthase (TS), breast cancer susceptibility gene 1 (BRCA1) and topoisomerase 1 (TOPO1), all in HT-29 and LoVo cells, with or without the addition of cinnamaldehyde, was examined by quantitative polymerase chain reaction (PCR).
|
24276478 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Epidemiological studies have evaluated the association between TYMS gene polymorphisms and breast cancer susceptibility; however, the published data are still inconclusive.
|
21188629 |
2011 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
|
15890242 |
2005 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The authors of this report investigated the relation of EGFR mutation or ALK rearrangement status and the expression of DNA repair or synthesis genes, including excision repair cross-complementing 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), thymidylate synthetase (TS), and breast cancer-early onset (BRCA1), as a potential explanation for these observations.
|
22569898 |
2012 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated polymorphisms that influenced the metabolism of taxane (ATP-binding cassette transporter B1 (ABCB1)), cisplatin (glutathione S-transferase M1 (GSTM1), glutathione S-transferase P1 (GSTP1), glutathione S-transferase T1 (GSTT1), excision repair cross complementing 1 (ERCC1), X-ray Cross Complementing group 3 (XRCC3), X-ray Cross Complementing group 4 (XRCC4), X-ray Cross Complementing group 1 (XRCC1), breast cancer (BRCA1)), and 5-fluorouracil (methylene tetrahydrofolate reductase (MTHFR), thymidylate synthase (TYMS)).
|
20331623 |
2010 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.
|
21501481 |
2011 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
To test the hypothesis that polymorphisms of the TYMS gene are associated with risk of breast cancer, we genotyped these two polymorphisms in a case-control study of 432 incident cases with invasive breast cancer and 473 cancer-free controls in a Chinese population.
|
16723031 |
2006 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Relationship between thymidylate synthase (TYMS) gene polymorphism and TYMS protein levels in patients with high-risk breast cancer.
|
21036767 |
2010 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Relationship between thymidylate synthase and p53 and response to FEC versus taxane adjuvant chemotherapy for breast carcinoma.
|
22233820 |
2011 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
|
19020767 |
2008 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expressions of excision repair cross-complementing-1 (ERCC1), class III beta-tubulin, breast cancer susceptibility gene I (BRCA1), and thymidylate synthase were investigated simultaneously in the pre-treatment endoscopic tumor biopsy samples.
|
27130464 |
2017 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To study the importance of TS expression in determining resistance to these agents, we have developed an MDA435 breast cancer-derived cell line with tetracycline-regulated expression of TS termed MTS-5.
|
11705873 |
2001 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vinorelbine upregulates TP and downregulates TS in breast cancer cells, thereby further sensitizing tumor cells to capecitabine, which indicated the proper order for sequential therapy should be N → X. Sixty patients were eligible for the phase II trial.
|
23053266 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The common MTHFR C677T and TS enhancer region polymorphisms were not risk factors for breast cancer in this patient cohort nor were they associated with phenotypic features or with prognosis.
|
15510613 |
2004 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Evaluation of sensitivity to 5-FU on the basis of thymidylate synthase (TS)/dihydropyrimidine dehydrogenase (DPD) activity and chromosomal analysis in micro tissue specimens of breast cancer.
|
15604991 |
2004 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TS activity in the gastric, colon, and non-small cell lung cancers was significantly higher than in matched non-cancerous tissue (P<0.0002), but there was no difference in TS expression between tumor and non-cancerous tissue from breast cancer patients.
|
14612954 |
2003 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cross-talk was observed between one-carbon and xenobiotic pathways in breast cancer (RFC 80 G>A, COMT H108L and TYMS 5'-UTR 28 bp tandem repeat) and SLE (CYP1A1 m1, MTRR 66 A>G and GSTT1).
|
25648260 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study shows that genotyping the TS or the MTHFR gene is of little value in the individual assessment of the use of adjuvant therapy in breast cancer patients.
|
17581305 |
2007 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Associations between clinical-pathological parameters and biomarkers, HER-2, TYMS, RRMI, and 21-gene recurrence score in breast cancer.
|
31551176 |
2019 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic screening of the drug metabolizing enzyme like TYMS for the presence of polymorphisms in breast cancer patients will become increasingly useful in individualizing drug therapy.
|
20571234 |
2010 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a nested case-control study of 380 women with incident breast cancer and 662 controls within the Singapore Chinese Health Study, we found no association between either green tea intake or gene polymorphisms of MTHFR (C677T and A1298C) and TYMS (1494 ins/del) and breast cancer risk.
|
18669903 |
2008 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We studied the expression of rTSbeta, a reverse orientation gene of TS, as a 5-FU resistance marker in patients with primary breast cancer.
|
18357371 |
2008 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In patient tissues, TS levels were found significantly higher in poorly differentiated and in triple negative BC, and strongly correlated with worse prognosis.
|
30737477 |
2019 |